Representatives from the Chinese side say they think it likely that Chinese President Xi Jinping will attend the G-20 meeting later this month. But in order to reach a trade...China Economyread more
Software engineers straight out of college often make six-figure salaries, not counting equity compensation.Technologyread more
Wall Street, though, is clamoring for a rate cut, with an 85% chance of a move in July and a 61% probability of three reductions by year's end.The Fedread more
A company spokesperson said the outage was the result of a "an internal technology issue" and was not security related.Retailread more
Using MIT's living wage calculator, CNBC Make It mapped out the minimum amount a single parent must earn to meet their basic needs without relying on outside help in every...Earnread more
The flattening of the yield curve is exuding a bad omen for the stock market if history is any guide.Marketsread more
Hong Kong Chief Executive Carrie Lam announced at a press conference on Saturday that a contentious bill to allow extraditions to mainland China has been put on hold.China Politicsread more
Stratolaunch, the world's largest airplane, which flew once, is up for sale, sources familiar told CNBC.Investing in Spaceread more
Transparency is key… or is it? With the first-ever non-transparent, actively managed exchange-traded fund receiving approval from the SEC, "ETF Edge" goes straight to the...ETF Edgeread more
Mired in a crisis over its best-selling 737 Max plane, Boeing could hand the spotlight over to its rival Airbus at the Paris Air Show.Airlinesread more
A new update to the Apple Watch called watchOS 6 will notify you if the environment you're in is too loud and could damage your hearing.Technologyread more
bladder cancer study@
June 3 (Reuters) - An experimental drug developed by Seattle Genetics Inc and Astellas Pharma Inc led to significant, rapid tumor shrinkage in patients with advanced bladder cancer who had been previously treated with immunotherapy and chemotherapy in a midstage trial, according to data presented on Monday.
In the 125-patient study of the drug, enfortumab vedotin, the overall response rate was 44%, meaning tumors were at least 30% smaller for those patients. That included a complete response, or no detectable cancer, for 12% of patients.
Responses were similar even among patients with the worst prognosis, including those whose cancer had spread to the liver, patients who had received three or more previous therapies and those who did not respond to treatment with an immuno-oncology drug, such as Merck & Co's Keytruda, researchers reported.
Current treatment options for those patients are extremely limited.
These data have the potential to change the treatment course of advanced urothelial (bladder) cancer, and it is gratifying to see these results for patients, Dr. Daniel Petrylak of the Yale Cancer Center, who led the study, said in a statement.
Enfortumab vedotin is a new type of treatment called an antibody-drug conjugate. It combines an antibody that targets a specific protein on the surface of tumor cells with a payload of chemotherapy that penetrates and kills cancer cells.
"Basically, it's a smart bomb," said Petrylak, who presented the data at the American Society of Clinical Oncology meeting in Chicago.
The companies, which share development costs and eventual profits, believe the data to be strong enough to seek accelerated approval with U.S. regulators this year.
They are enrolling patients for a confirmatory late-stage trial testing the drug against standard chemotherapy.
"Our priority is to focus on areas with high unmet need and pursue targeted therapies for hard-to-treat cancers where few therapies exist," Andrew Krivoshik, head of oncology for Japan-based Astellas said in a phone interview.
For Seattle Genetics, which received its first approval for a drug to treat lymphoma last year, enfortumab vedotin's approval would expand its portfolio into solid tumor cancers.
In addition to presenting tumor response data - the primary goal of the trial - researchers said most responses occurred within the first cycle of treatment and reported an overall duration of response of 7.6 months.
While the trial was not designed to demonstrate a statistically significant benefit on overall survival, half the patients were still alive after 11.7 months. Typical median overall survival for metastatic bladder cancer is about 9 months.
Researchers were particularly encouraged by the significant tumor shrinkage seen in 38% of patients whose bladder cancer had spread to the liver, as they tend to be among the most difficult to treat with a very poor prognosis.
The American Cancer Society estimates 17,670 people will die from bladder cancer in the United States this year. (Reporting by Tamara Mathias in Bengaluru; editing by Bill Berkrot)